Skip to main content
Erschienen in: Archives of Dermatological Research 8/2019

01.06.2019 | Original Paper

Macrophage migration inhibitory factor polymorphism (rs755622) in alopecia areata: a possible role in disease prevention

verfasst von: Fateme Rajabi, Mahsa M. Amoli, Reza M. Robati, Mina Almasi-nasrabadi, Navid Jabalameli

Erschienen in: Archives of Dermatological Research | Ausgabe 8/2019

Einloggen, um Zugang zu erhalten

Abstract

Alopecia areata (AA) is an organ-specific autoimmune disease that targets the bulb of the hair follicles and results in non-scarring hair loss that can range from patchy lesions to involvement of the entire scalp. AA develops when the hair follicles lose their physiologic state of immune privilege. One of the key factors that help in maintaining this immune privilege by suppressing natural killer cells is macrophage migration inhibitory factor (MIF). Surprisingly, MIF is also known to provoke autoimmunity by upregulating cytokines. To address this dilemma and understand the exact nature of the involvement of MIF in disease pathogenesis we investigated the association of MIF gene polymorphisms (− 173 G > C, rs755622) with AA by conducting a case–control study of 274 subjects. We observed that the frequency of the C allele in the patients was significantly lower than the control group (0.15, 0.23, respectively, p = 0.01) and the combined frequencies of the CC and GC genotypes (dominant Mendelian pattern) had the most prevalent difference between the two groups (odds ratio 0.60, 95% confidence interval 0.36–0.99; p = 0.048).Since the C allele is associated with higher MIF transcription levels, this could infer that MIF is more likely to attribute to the preservation of the immune privilege rather than acting as a proinflammatory factor.
Literatur
1.
Zurück zum Zitat Apte RS, Sinha D, Mayhew E, Wistow G, Niederkorn J (1998) Cutting edge: role of macrophage migration inhibitory factor in inhibiting NK cell activity and preserving immune privilege. J Immunol 160:5693–5696PubMed Apte RS, Sinha D, Mayhew E, Wistow G, Niederkorn J (1998) Cutting edge: role of macrophage migration inhibitory factor in inhibiting NK cell activity and preserving immune privilege. J Immunol 160:5693–5696PubMed
2.
Zurück zum Zitat Arcuri F, Cintorino M, Carducci A, Papa S, Riparbelli M, Mangioni S, Di Blasio A, Tosi P, Vigano P (2006) Human decidual natural killer cells as a source and target of macrophage migration inhibitory factor. Reproduction 131:175–182CrossRefPubMed Arcuri F, Cintorino M, Carducci A, Papa S, Riparbelli M, Mangioni S, Di Blasio A, Tosi P, Vigano P (2006) Human decidual natural killer cells as a source and target of macrophage migration inhibitory factor. Reproduction 131:175–182CrossRefPubMed
3.
Zurück zum Zitat Denkinger CM, Metz C, Fingerle-Rowson G, Denkinger MD, Forsthuber T (2004) Macrophage migration inhibitory factor and its role in autoimmune diseases. Arch Immunol Ther Exp (Warsz) 52:389–400 Denkinger CM, Metz C, Fingerle-Rowson G, Denkinger MD, Forsthuber T (2004) Macrophage migration inhibitory factor and its role in autoimmune diseases. Arch Immunol Ther Exp (Warsz) 52:389–400
4.
Zurück zum Zitat Donn R, Alourfi Z, De Benedetti F, Meazza C, Zeggini E, Lunt M, Stevens A, Shelley E, Lamb R, Ollier WE (2002) Mutation screening of the macrophage migration inhibitory factor gene: positive association of a functional polymorphism of macrophage migration inhibitory factor with juvenile idiopathic arthritis. Arthritis Rheumatol 46:2402–2409CrossRef Donn R, Alourfi Z, De Benedetti F, Meazza C, Zeggini E, Lunt M, Stevens A, Shelley E, Lamb R, Ollier WE (2002) Mutation screening of the macrophage migration inhibitory factor gene: positive association of a functional polymorphism of macrophage migration inhibitory factor with juvenile idiopathic arthritis. Arthritis Rheumatol 46:2402–2409CrossRef
5.
Zurück zum Zitat Donn R, Shelley E, Ollier W, Thomson W, Group BPRS (2001) A novel 5′-flanking region polymorphism of macrophage migration inhibitory factor is associated with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 44:1782–1785CrossRef Donn R, Shelley E, Ollier W, Thomson W, Group BPRS (2001) A novel 5′-flanking region polymorphism of macrophage migration inhibitory factor is associated with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 44:1782–1785CrossRef
6.
Zurück zum Zitat Donn RP, Plant D, Jury F, Richards HL, Worthington J, Ray DW, Griffiths CE (2004) Macrophage migration inhibitory factor gene polymorphism is associated with psoriasis. J Invest Dermatol 123:484–487CrossRefPubMed Donn RP, Plant D, Jury F, Richards HL, Worthington J, Ray DW, Griffiths CE (2004) Macrophage migration inhibitory factor gene polymorphism is associated with psoriasis. J Invest Dermatol 123:484–487CrossRefPubMed
7.
Zurück zum Zitat Donnelly SC, Bucala R (1997) Macrophage migration inhibitory factor: a regulator of glucocorticoid activity with a critical role in inflammatory disease. Mol Med Today 3:502–507CrossRefPubMed Donnelly SC, Bucala R (1997) Macrophage migration inhibitory factor: a regulator of glucocorticoid activity with a critical role in inflammatory disease. Mol Med Today 3:502–507CrossRefPubMed
8.
Zurück zum Zitat Foote A, Briganti EM, Kipen Y, Santos L, Leech M, Morand EF (2004) Macrophage migration inhibitory factor in systemic lupus erythematosus. J Rheumatol 31:268–273PubMed Foote A, Briganti EM, Kipen Y, Santos L, Leech M, Morand EF (2004) Macrophage migration inhibitory factor in systemic lupus erythematosus. J Rheumatol 31:268–273PubMed
9.
Zurück zum Zitat Gilhar A (2010) Collapse of immune privilege in alopecia areata: coincidental or substantial? J Invest Dermatol 130:2535–2537CrossRefPubMed Gilhar A (2010) Collapse of immune privilege in alopecia areata: coincidental or substantial? J Invest Dermatol 130:2535–2537CrossRefPubMed
10.
Zurück zum Zitat Greven D, Leng L, Bucala R (2010) Autoimmune diseases: MIF as a therapeutic target. Expert Opin Ther Tar 14:253–264CrossRef Greven D, Leng L, Bucala R (2010) Autoimmune diseases: MIF as a therapeutic target. Expert Opin Ther Tar 14:253–264CrossRef
11.
Zurück zum Zitat Illescas O, Gomez-Verjan JC, García-Velázquez L, Govezensky T, Rodriguez-Sosa M (2018) Macrophage migration inhibitory factor – 173 G/C polymorphism: a global meta-analysis across the disease spectrum. Front Genet 9:55CrossRefPubMedPubMedCentral Illescas O, Gomez-Verjan JC, García-Velázquez L, Govezensky T, Rodriguez-Sosa M (2018) Macrophage migration inhibitory factor – 173 G/C polymorphism: a global meta-analysis across the disease spectrum. Front Genet 9:55CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Ito T, Ito N, Bettermann A, Tokura Y, Takigawa M, Paus R (2004) Collapse and restoration of MHC class-I-dependent immune privilege: exploiting the human hair follicle as a model. Am J Pathol 164:623–634CrossRefPubMedPubMedCentral Ito T, Ito N, Bettermann A, Tokura Y, Takigawa M, Paus R (2004) Collapse and restoration of MHC class-I-dependent immune privilege: exploiting the human hair follicle as a model. Am J Pathol 164:623–634CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Ito T, Ito N, Saathoff M, Stampachiacchiere B, Bettermann A, Bulfone-Paus S, Takigawa M, Nickoloff BJ, Paus R (2005) Immunology of the human nail apparatus: the nail matrix is a site of relative immune privilege. J Invest Dermatol 125:1139–1148CrossRefPubMed Ito T, Ito N, Saathoff M, Stampachiacchiere B, Bettermann A, Bulfone-Paus S, Takigawa M, Nickoloff BJ, Paus R (2005) Immunology of the human nail apparatus: the nail matrix is a site of relative immune privilege. J Invest Dermatol 125:1139–1148CrossRefPubMed
14.
Zurück zum Zitat Ito T, Ito N, Saatoff M, Hashizume H, Fukamizu H, Nickoloff BJ, Takigawa M, Paus R (2008) Maintenance of hair follicle immune privilege is linked to prevention of NK cell attack. J Invest Dermatol 128:1196–1206CrossRefPubMed Ito T, Ito N, Saatoff M, Hashizume H, Fukamizu H, Nickoloff BJ, Takigawa M, Paus R (2008) Maintenance of hair follicle immune privilege is linked to prevention of NK cell attack. J Invest Dermatol 128:1196–1206CrossRefPubMed
15.
Zurück zum Zitat Kang H, Wu W-Y, Lo BK, Yu M, Leung G, Shapiro J, McElwee KJ (2010) Hair follicles from alopecia areata patients exhibit alterations in immune privilege-associated gene expression in advance of hair loss. J Invest Dermatol 130:2677–2680CrossRefPubMed Kang H, Wu W-Y, Lo BK, Yu M, Leung G, Shapiro J, McElwee KJ (2010) Hair follicles from alopecia areata patients exhibit alterations in immune privilege-associated gene expression in advance of hair loss. J Invest Dermatol 130:2677–2680CrossRefPubMed
16.
Zurück zum Zitat Leech M, Metz C, Bucala R, MorAnd EF (2000) Regulation of macrophage migration inhibitory factor by endogenous glucocorticoids in rat adjuvant-induced arthritis. Arthritis Rheumatol 43:827–833CrossRef Leech M, Metz C, Bucala R, MorAnd EF (2000) Regulation of macrophage migration inhibitory factor by endogenous glucocorticoids in rat adjuvant-induced arthritis. Arthritis Rheumatol 43:827–833CrossRef
17.
Zurück zum Zitat Matia-García I, Salgado-Goytia L, Muñoz-Valle JF, García-Arellano S, Hernández-Bello J, Salgado-Bernabé AB, Parra-Rojas I (2015) Macrophage migration inhibitory factor promoter polymorphisms (-794 CATT 5–8 and-173 G> C): relationship with mRNA expression and soluble MIF levels in young obese subjects. Dis Markers 2015:461208CrossRefPubMedPubMedCentral Matia-García I, Salgado-Goytia L, Muñoz-Valle JF, García-Arellano S, Hernández-Bello J, Salgado-Bernabé AB, Parra-Rojas I (2015) Macrophage migration inhibitory factor promoter polymorphisms (-794 CATT 5–8 and-173 G> C): relationship with mRNA expression and soluble MIF levels in young obese subjects. Dis Markers 2015:461208CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Meyer K, Klatte J, Dinh H, Harries M, Reithmayer K, Meyer W, Sinclair R, Paus R (2008) Evidence that the bulge region is a site of relative immune privilege in human hair follicles. Br J Dermatol 159:1077–1085PubMed Meyer K, Klatte J, Dinh H, Harries M, Reithmayer K, Meyer W, Sinclair R, Paus R (2008) Evidence that the bulge region is a site of relative immune privilege in human hair follicles. Br J Dermatol 159:1077–1085PubMed
19.
Zurück zum Zitat Mirzoyev SA, Schrum AG, Davis MD, Torgerson RR (2014) Lifetime incidence risk of alopecia areata estimated at 2.1 percent by rochester epidemiology project, 1990–2009. J Invest Dermatol 134:1141CrossRefPubMed Mirzoyev SA, Schrum AG, Davis MD, Torgerson RR (2014) Lifetime incidence risk of alopecia areata estimated at 2.1 percent by rochester epidemiology project, 1990–2009. J Invest Dermatol 134:1141CrossRefPubMed
20.
Zurück zum Zitat Morales-Zambrano R, Bautista-Herrera LA, De la Cruz-Mosso U, Villanueva-Quintero GD, Padilla-Gutiérrez JR, Valle Y, Parra-Rojas I, Rangel-Villalobos H, Gutiérrez-Ureña SR, Muñoz-Valle JF (2014) Macrophage migration inhibitory factor (MIF) promoter polymorphisms (− 794 CATT5–8 and – 173 G > C): association with MIF and TNFα in psoriatic arthritis. Int J Clin Exp Med 7:2605PubMedPubMedCentral Morales-Zambrano R, Bautista-Herrera LA, De la Cruz-Mosso U, Villanueva-Quintero GD, Padilla-Gutiérrez JR, Valle Y, Parra-Rojas I, Rangel-Villalobos H, Gutiérrez-Ureña SR, Muñoz-Valle JF (2014) Macrophage migration inhibitory factor (MIF) promoter polymorphisms (− 794 CATT5–8 and – 173 G > C): association with MIF and TNFα in psoriatic arthritis. Int J Clin Exp Med 7:2605PubMedPubMedCentral
21.
Zurück zum Zitat Murakami H, Akbar SMF, Matsui H, Onji M (2001) Macrophage migration inhibitory factor in the sera and at the colonic mucosa in patients with ulcerative colitis: clinical implications and pathogenic significance. Eur J Clin Invest 31:337–343CrossRefPubMed Murakami H, Akbar SMF, Matsui H, Onji M (2001) Macrophage migration inhibitory factor in the sera and at the colonic mucosa in patients with ulcerative colitis: clinical implications and pathogenic significance. Eur J Clin Invest 31:337–343CrossRefPubMed
22.
Zurück zum Zitat Namazi MR, Fallahzadeh MK, Shaghelani H, Kamali-Sarvestani E (2010) Marked elevation of serum macrophage migration inhibitory factor levels in patients with pemphigus vulgaris. Int J Dermatol 49:146–148CrossRefPubMed Namazi MR, Fallahzadeh MK, Shaghelani H, Kamali-Sarvestani E (2010) Marked elevation of serum macrophage migration inhibitory factor levels in patients with pemphigus vulgaris. Int J Dermatol 49:146–148CrossRefPubMed
23.
Zurück zum Zitat Ohwatari R, Inuyama Y, Fukuda S, Onoé K, Iwabuchi K, Nishihira J (2001) Serum level of macrophage migration inhibitory factor as a useful parameter of clinical course in patients with Wegener’s granulomatosis and relapsing polychondritis. Ann Oto Rhinol Laryn 110:1035–1040CrossRef Ohwatari R, Inuyama Y, Fukuda S, Onoé K, Iwabuchi K, Nishihira J (2001) Serum level of macrophage migration inhibitory factor as a useful parameter of clinical course in patients with Wegener’s granulomatosis and relapsing polychondritis. Ann Oto Rhinol Laryn 110:1035–1040CrossRef
24.
Zurück zum Zitat Olsen EA, Hordinsky MK, Price VH, Roberts JL, Shapiro J, Canfield D, Duvic M, King LE, McMichael AJ, Randall VA (2004) Alopecia areata investigational assessment guidelines-part II. J Am Acad Dermatol 51:440–447CrossRefPubMed Olsen EA, Hordinsky MK, Price VH, Roberts JL, Shapiro J, Canfield D, Duvic M, King LE, McMichael AJ, Randall VA (2004) Alopecia areata investigational assessment guidelines-part II. J Am Acad Dermatol 51:440–447CrossRefPubMed
25.
Zurück zum Zitat Petukhova L, Duvic M, Hordinsky M, Norris D, Price V, Shimomura Y, Kim H, Singh P, Lee A, Chen WV (2010) Genome-wide association study in alopecia areata implicates both innate and adaptive immunity. Nature 466:113CrossRefPubMedPubMedCentral Petukhova L, Duvic M, Hordinsky M, Norris D, Price V, Shimomura Y, Kim H, Singh P, Lee A, Chen WV (2010) Genome-wide association study in alopecia areata implicates both innate and adaptive immunity. Nature 466:113CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat Rajabi F, Drake L, Senna M, Rezaei N (2018) Alopecia areata: a review of disease pathogenesis. Br J Dermatol 179:1033–1048CrossRefPubMed Rajabi F, Drake L, Senna M, Rezaei N (2018) Alopecia areata: a review of disease pathogenesis. Br J Dermatol 179:1033–1048CrossRefPubMed
28.
Zurück zum Zitat Repp AC, Mayhew ES, Apte S, Niederkorn JY (2000) Human uveal melanoma cells produce macrophage migration-inhibitory factor to prevent lysis by NK cells. J Immunol 165:710–715CrossRefPubMed Repp AC, Mayhew ES, Apte S, Niederkorn JY (2000) Human uveal melanoma cells produce macrophage migration-inhibitory factor to prevent lysis by NK cells. J Immunol 165:710–715CrossRefPubMed
29.
Zurück zum Zitat Saeedi M, Amoli M, Robati R, Sayahpour F, Namazi N, Toossi P (2013) Macrophage migration inhibitory factor gene polymorphism is not associated with pemphigus vulgaris in Iranian patients. J Eur Acad Dermatol Venereol 27:1127–1131CrossRefPubMed Saeedi M, Amoli M, Robati R, Sayahpour F, Namazi N, Toossi P (2013) Macrophage migration inhibitory factor gene polymorphism is not associated with pemphigus vulgaris in Iranian patients. J Eur Acad Dermatol Venereol 27:1127–1131CrossRefPubMed
30.
Zurück zum Zitat Salem SA, Asaad MK, Elsayed SB, Sehsah HM (2016) Evaluation of macrophage migration inhibitory factor (MIF) levels in serum and lesional skin of patients with alopecia areata. Int J Dermatol 55:1357–1361CrossRefPubMed Salem SA, Asaad MK, Elsayed SB, Sehsah HM (2016) Evaluation of macrophage migration inhibitory factor (MIF) levels in serum and lesional skin of patients with alopecia areata. Int J Dermatol 55:1357–1361CrossRefPubMed
31.
Zurück zum Zitat Shimizu T, Abe R, Ohkawara A, Nishihira J (1999) Increased production of macrophage migration inhibitory factor by PBMCs of atopic dermatitis. J Allergy Clin Immun 104:659–664CrossRefPubMed Shimizu T, Abe R, Ohkawara A, Nishihira J (1999) Increased production of macrophage migration inhibitory factor by PBMCs of atopic dermatitis. J Allergy Clin Immun 104:659–664CrossRefPubMed
32.
Zurück zum Zitat Shimizu T, Hizawa N, Honda A, Zhao Y, Abe R, Watanabe H, Nishihira J, Nishimura M, Shimizu H (2005) Promoter region polymorphism of macrophage migration inhibitory factor is strong risk factor for young onset of extensive alopecia areata. Genes Immun 6:285–289CrossRefPubMed Shimizu T, Hizawa N, Honda A, Zhao Y, Abe R, Watanabe H, Nishihira J, Nishimura M, Shimizu H (2005) Promoter region polymorphism of macrophage migration inhibitory factor is strong risk factor for young onset of extensive alopecia areata. Genes Immun 6:285–289CrossRefPubMed
33.
Zurück zum Zitat Shimizu T, Mizue Y, Abe R, Watanabe H, Shimizu H (2002) Increased macrophage migration inhibitory factor (MIF) in the sera of patients with extensive alopecia areata. J Invest Dermatol 118:555CrossRefPubMed Shimizu T, Mizue Y, Abe R, Watanabe H, Shimizu H (2002) Increased macrophage migration inhibitory factor (MIF) in the sera of patients with extensive alopecia areata. J Invest Dermatol 118:555CrossRefPubMed
34.
Zurück zum Zitat Shimizu T, Nishihira J, Mizue Y, Nakamura H, Abe R, Watanabe H, Ohkawara A, Shimizu H (2001) High macrophage migration inhibitory factor (MIF) serum levels associated with extended psoriasis. J Invest Dermatol 116:989–990CrossRefPubMed Shimizu T, Nishihira J, Mizue Y, Nakamura H, Abe R, Watanabe H, Ohkawara A, Shimizu H (2001) High macrophage migration inhibitory factor (MIF) serum levels associated with extended psoriasis. J Invest Dermatol 116:989–990CrossRefPubMed
35.
Zurück zum Zitat Shimizu T, Nishihira J, Mizue Y, Nakamura H, Abe R, Watanabe H, Ohkawara A, Shimizu H (2001) High macrophage migration inhibitory factor (MIF) serum levels associated with extended psoriasis. J Invest Dermatol 116:989–990CrossRefPubMed Shimizu T, Nishihira J, Mizue Y, Nakamura H, Abe R, Watanabe H, Ohkawara A, Shimizu H (2001) High macrophage migration inhibitory factor (MIF) serum levels associated with extended psoriasis. J Invest Dermatol 116:989–990CrossRefPubMed
36.
Zurück zum Zitat Stosic-Grujicic S, Stojanovic I, Maksimovic-Ivanic D, Momcilovic M, Popadic D, Harhaji L, Miljkovic D, Metz C, Mangano K, Papaccio G (2008) Macrophage migration inhibitory factor (MIF) is necessary for progression of autoimmune diabetes mellitus. J Cell Physiol 215:665–675CrossRefPubMed Stosic-Grujicic S, Stojanovic I, Maksimovic-Ivanic D, Momcilovic M, Popadic D, Harhaji L, Miljkovic D, Metz C, Mangano K, Papaccio G (2008) Macrophage migration inhibitory factor (MIF) is necessary for progression of autoimmune diabetes mellitus. J Cell Physiol 215:665–675CrossRefPubMed
37.
Zurück zum Zitat Streilein JW (2003) Ocular immune privilege: therapeutic opportunities from an experiment of nature. Nat Rev Immunol 3:879CrossRefPubMed Streilein JW (2003) Ocular immune privilege: therapeutic opportunities from an experiment of nature. Nat Rev Immunol 3:879CrossRefPubMed
38.
Zurück zum Zitat Younan DNA, Agamia N, Elshafei A, Ebeid N (2015) Serum level of macrophage migration inhibitory factor (MIF) in Egyptians with alopecia areata and its relation to the clinical severity of the disease. J Clin Lab Anal 29:74–79CrossRefPubMed Younan DNA, Agamia N, Elshafei A, Ebeid N (2015) Serum level of macrophage migration inhibitory factor (MIF) in Egyptians with alopecia areata and its relation to the clinical severity of the disease. J Clin Lab Anal 29:74–79CrossRefPubMed
Metadaten
Titel
Macrophage migration inhibitory factor polymorphism (rs755622) in alopecia areata: a possible role in disease prevention
verfasst von
Fateme Rajabi
Mahsa M. Amoli
Reza M. Robati
Mina Almasi-nasrabadi
Navid Jabalameli
Publikationsdatum
01.06.2019
Verlag
Springer Berlin Heidelberg
Erschienen in
Archives of Dermatological Research / Ausgabe 8/2019
Print ISSN: 0340-3696
Elektronische ISSN: 1432-069X
DOI
https://doi.org/10.1007/s00403-019-01934-9

Weitere Artikel der Ausgabe 8/2019

Archives of Dermatological Research 8/2019 Zur Ausgabe

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Hirsutismus bei PCOS: Laser- und Lichttherapien helfen

26.04.2024 Hirsutismus Nachrichten

Laser- und Lichtbehandlungen können bei Frauen mit polyzystischem Ovarialsyndrom (PCOS) den übermäßigen Haarwuchs verringern und das Wohlbefinden verbessern – bei alleiniger Anwendung oder in Kombination mit Medikamenten.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

22.04.2024 DGIM 2024 Nachrichten

Um Menschen nach der Flucht aus einem Krisengebiet bestmöglich medizinisch betreuen zu können, ist es gut zu wissen, welche Erkrankungen im jeweiligen Herkunftsland häufig sind. Dabei hilft eine Internetseite der CDC (Centers for Disease Control and Prevention).

Kein Abstrich bei chronischen Wunden ohne Entzündungszeichen!

16.04.2024 DGIM 2024 Nachrichten

Den Reflex, eine oberflächliche chronische Hautwunde ohne Entzündungszeichen in jedem Fall abzustreichen, sollte man nach einer neuen „Klug-entscheiden“-Empfehlung unterdrücken.

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.